ArticleFrontiers in pediatrics2025
The safety of high dose continuous propofol infusion in the pediatric intensive care unit at an academic medical center.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Adequate sedation is crucial in the care of critically ill children. Propofol, known for its rapid onset, reliable patient response, and short duration of action, offers an attractive pharmacologic profile. However, concerns for propofol-related infusion syndrome (PRIS) have limited its use in pediatric critical care. This study examined the relationship between propofol administration and PRIS characteristics in a single medical-surgical pediatric intensive care unit (PICU). We hypothesized that continuous propofol infusion, even when judiciously exceeding current recommended doses and durations, is not associated with cardiovascular collapse, metabolic acidosis, or other PRIS-related characteristics. Methods: This is a retrospective single-center study in the non-cardiac medical/surgical PICU at a tertiary academic medical center of 554 patients. Children aged 0-17 years admitted to the PICU from 1/1/2000 to 9/30/2024, who received propofol infusions for ≥12 h and/or ≥2.4 mg/kg/hour (40 mcg/kg/min) were included. The primary outcome was in-hospital mortality; secondary outcomes included intensive care unit (ICU) length of stay, bradycardia during infusion, and metabolic acidosis during infusion. Data was compared across age groups (<6 months, 6-12 months, 1-5 years, 6-17 years) and medical/surgical diagnosis using the chi-square test for homogeneity and the Kruskal-Wallis tests. Results: Among 554 patients, the median age was 5.5 (IQR 1.5-12.1) years. The median propofol infusion rate was 3.0 (IQR 1.7-4.2) mg/kg/hour [50 (IQR 28-70) mcg/kg/min], median duration was 22.8 (IQR 16.4-42.4) hours, and median ICU length of stay was 4.7 (IQR 2.0-10.4) days. One case of PRIS was observed (0.2%). There were 26 (4.7%) in-hospital deaths, nonattributable to PRIS. Bradycardia occurred in 146 (26.4%) patients, and 19 (3.4%) patients developed metabolic acidosis. Discussion: In this single-center retrospective study, one case of PRIS was identified. While rare, its occurrence underscores the need for vigilance. Propofol remains a viable sedation option when used with appropriate monitoring in pediatric critical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.